Early-stage serology Velox Biosystems has launched a cutting-edge serological testing service and is actively developing COVID-19 countermeasures, presenting a potential entry point for diagnostic collaborations, contract development, and rapid testing deployments with healthcare providers and laboratories.

IC3D platform The Integrated Comprehensive Droplet Digital Detection system offers high sensitivity and direct sample processing, enabling faster, automated pathogen detection across bacteria, viruses, neurological, and cancer biomarkers—appealing to labs seeking streamlined, high-throughput diagnostics.

Small team, agility With a Lean headcount and a startup footprint, Velox can be a partner for pilot programs, quick iteration projects, and co-development efforts, leveraging targeted collaborations to scale technology adoption without large enterprise overhead.

Digital tech stack Reliance on common web, data, and development tools (WordPress, MySQL, jQuery, PHP) suggests a cost-effective, flexible approach to software and data integration, enabling partnerships around data management, reporting dashboards, and remote monitoring of diagnostic tests.

Funding signals Current revenue range is modest, indicating early commercial traction with significant growth potential; sales efforts can emphasize expanded test menus, enterprise lab contracts, and multi-site deployments to accelerate revenue scale.